Physician profile
Eric Isenman
NPI 1609931187
$806.71
in general payments reported to CMS, 2019-2025
15 companies · $356 in 2025
The $356 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $333 · 2020: $74.16 · 2023: $43.83 · 2025: $356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $399.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $179.13 | 2019-2025 | Ozempic, Rybelsus |
| Phathom Pharmaceuticals, INC. | $128.87 | 2025 | Voquezna |
| Amgen INC. | $107.20 | 2019-2025 | Evenity, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.91 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $55.49 | 2020-2025 | Breztri |
| Lilly USA, LLC | $53.16 | 2019-2025 | Mounjaro |
| Novartis Pharmaceuticals Corporation | $52.34 | 2019 | |
| Abbvie INC. | $36.05 | 2023-2025 | |
| Pfizer INC. | $28.03 | 2019-2025 | |
| Hologic Sales and Service, LLC | $22.43 | 2023 | Thinprep 2000 Processor, Aptima |
| Amarin Pharma, INC. | $18.05 | 2019 | |
| Biotronik INC. | $17.75 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $14.65 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.53 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Isenman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.